Evidence map›Paper›PMID 42113844›Full record

ArticlePLoS pathogens2026

Host species-specific mutations in the thumb domain of the 3Dpol polymerase are required for efficient replication of human hepatitis A virus in mice.

Ichiro Misumi, Takayoshi Shirasaki, Ling Xie, Bryan Yonish, Olga González-López, Asuka Hirai-Yuki, Xian Chen, You Li, Jason K Whitmire, Stanley M Lemon

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ichiro MisumiDepartment of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Takayoshi ShirasakiDepartment of Microbiology & Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Ling XieDepartment of Biochemistry and Biophysics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Bryan YonishLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Olga González-LópezDepartment of Microbiology & Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Asuka Hirai-YukiDepartment of Microbiology & Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Xian ChenDepartment of Biochemistry and Biophysics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
You LiDepartment of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Jason K WhitmireDepartment of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Stanley M LemonDepartment of Microbiology & Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.ORCID https://orcid.org/0000-0003-1450-806X

Funding

Antiviral inhibition of ZCCHC14-TENT4 complex in hepatitis A virus infectionR21AI163606 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, YOU, MISUMI, ICHIRO · 2021 to 2022
$428k
NIAID NIH HHS R21 AI163606
6 · The paper itself

Abstract

Hepatitis A virus (HAV) is a globally important cause of enterically-transmitted hepatitis. It is one of 9 distinct Hepatovirus species in the Picornaviridae, among which phylogenetic reconstructions suggest multiple past host species jumps. HAV readily infects mice with defective type I interferon responses, suggesting the major barrier preventing human HAV from replicating in a rodent host is an inability to overcome innate immune responses. In prior studies, only a single nonsynonymous mutation of uncertain significance (3Dpol-R468K) was identified within the genome of wild-type HAV following passage in interferon-receptor knockout mice. Here, we show that R468K and other mutations in the 3Dpol polymerase (E461D and D473G) are uniformly present in virus recovered from Ifnar1-/- mice following intrahepatic injection of HAV RNA. Reverse molecular genetics experiments confirmed RNAs with R468K or D473G mutations were more likely to initiate sustained infection than wild-type RNA in mice. In competition experiments using cell culture-adapted virus, a K468 mutant out-replicated wild-type R468 in murine cells, whereas R468 rapidly replaced K468 in human cells. These 3Dpol mutations thus promote HAV replication in a host species-specific manner. AlphaFold 3 modeling indicates E461, R468, and D473 are closely positioned on the surface of the 3Dpol thumb domain, suggesting they modulate interactions with species-specific host factor(s). Proteomics analysis of proteins co-precipitating with HA-3Dpol expressed in Huh-7.5 cells identified heat shock 70 protein HSPA8 and its co-chaperone, BAG2. HSPA8 is known to be a critical hepatovirus host factor and HAV genome replication is highly dependent upon heat shock chaperone activity. The mouse-adaptive R468K mutation enhances co-immunoprecipitation of 3Dpol with murine HSPA8 and BAG2, suggesting it facilitates chaperone-dependent acquisition of polymerase function in mouse cells. Our results identify a non-immune barrier to HAV replication in mice and enable future reverse molecular genetics studies in a small animal model.

Indexed as

Hepatitis A virusMutationRNA-Dependent RNA PolymeraseViral ProteinsVirus ReplicationAnimalsHost SpecificityHumansMiceMice, KnockoutSpecies SpecificityRNA-Dependent RNA PolymeraseViral Proteins

Identifiers

PMID42113844
PMCPMC13175494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.